John Hawkins
Geen lopende functies
Vermogen: 8 452 $ op 29-02-2024
Oorsprong van het eerstegraads netwerk van John Hawkins
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 24 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met John Hawkins via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
Zeneus Pharma Ltd.
 Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | Medical Distributors | Founder Chief Tech/Sci/R&D Officer | |
| SAREUM HOLDINGS PLC | Miscellaneous | Chairman Director/Board Member | |
| Antisoma Research Ltd. | Corporate Officer/Principal General Counsel | ||
| TIGENIX NV | Medical Specialties | Director of Finance/CFO | |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Founder Chief Tech/Sci/R&D Officer | |
| United Kingdom Department of Health & Social Care | General Government | Corporate Officer/Principal | |
| OXFORD BIOMEDICA PLC | Biotechnology | Public Communications Contact | |
| University of Oxford | College/University | Undergraduate Degree Undergraduate Degree | |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Imperial College London | College/University | Graduate Degree Undergraduate Degree | |
Excalibur Fund Managers Ltd.
 Excalibur Fund Managers Ltd. Investment ManagersFinance Excalibur Fund Managers Ltd (Excalibur) is a venture capital firm founded in 1996 by Christopher Evans. The firm is headquartered in London, United Kingdom. | Investment Managers | Director/Board Member Founder | |
| University of Cambridge | College/University | Undergraduate Degree Doctorate Degree | |
| PHYSIOMICS PLC | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| University of Leeds | College/University | Doctorate Degree | |
| University of London | College/University | Undergraduate Degree Graduate Degree | |
ReNeuron Ltd.
 ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| University College London | College/University | Undergraduate Degree | |
| WEIFA ASA | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
| University of Bocconi | College/University | Doctorate Degree | |
| London Business School | College/University | Masters Business Admin Corporate Officer/Principal | |
| University of Hertfordshire | College/University | Undergraduate Degree | |
| King's College London | College/University | Doctorate Degree | |
| BANCO SANTANDER, S.A. | Major Banks | Corporate Officer/Principal | |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director of Finance/CFO | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor | |
| The University of Law Ltd. | College/University | Graduate Degree | |
HRA Pharma Development SARL
 HRA Pharma Development SARL Pharmaceuticals: MajorHealth Technology HRA Pharma Development SARL develops medicines and products for women's health and endocrinology. It offers emergency contraception, uterine fibroids, regular contraception, intimate health, genital herpes, and Lysosafe service. The company was founded by André Ulmann in 1996 and is headquartered in Châtillon, France. | Pharmaceuticals: Major | Director/Board Member | |
GlaxoSmithKline Services Unlimited
 GlaxoSmithKline Services Unlimited Pharmaceuticals: MajorHealth Technology Glaxosmithkline Services Unlimited Ltd. develops, manufactures and markets pharmaceutical products. The company was incorporated on March 23, 1972 and is headquartered in Brentford, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| REDX PHARMA PLC | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
ReNeuron (UK) Ltd.
 ReNeuron (UK) Ltd. BiotechnologyHealth Technology Part of ReNeuron Group Plc, ReNeuron (UK) Ltd. engages in research and experimental development on biotechnology. The company is based in Bridgend, UK and was founded in 2000. | Biotechnology | Director/Board Member Director/Board Member | |
| OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Nodenza, Inc. | Chief Tech/Sci/R&D Officer | ||
| Nerve Tumours Uk | Director/Board Member | ||
Neurocentrx Pharma Ltd.
 Neurocentrx Pharma Ltd. Pharmaceuticals: MajorHealth Technology Neurocentrx Pharma Ltd. is a British pharmaceutical company that manufactures and distributes medicines. The company is based in Edinburgh, UK. Neurocentrx Pharma was founded by Howard Marriage, Ronald M. Lindsay, and Carmel Reilly. Carmel Reilly has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
Peel Hunt LLP
 Peel Hunt LLP Investment Banks/BrokersFinance Peel Hunt LLP is an independent securities brokerage firm headquartered in London, UK. The firm was founded in 1989 as a market liquidity provider to retail and institutional investors. They provide bespoke dealing and execution services for institutional asset managers, registrars, private client wealth managers and private banks. | Investment Banks/Brokers | Sales & Marketing | |
| BENEVOLENTAI | Biotechnology | Director of Finance/CFO | |
Izana Bioscience Ltd.
 Izana Bioscience Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Izana Bioscience Ltd. is a British biotech company. The company is based in London, UK. The company's website, izanabio.com, provides general information about the company. The company was founded in 2017 by Someit Sidhu. Someit Sidhu has been the CEO since 2017. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Founder | |
Ernst & Young LLC
 Ernst & Young LLC Financial ConglomeratesFinance Ernst & Young LLC is a private group led by the management of Nuance Investments LLC. | Financial Conglomerates | Corporate Officer/Principal |
Statistieken
Internationaal
| Verenigd Koninkrijk | 33 |
| Verenigde Staten | 6 |
| Spanje | 4 |
| België | 3 |
| Zwitserland | 3 |
Sectoraal
| Health Technology | 19 |
| Consumer Services | 12 |
| Finance | 8 |
| Commercial Services | 4 |
| Distribution Services | 2 |
Operationeel
| Director/Board Member | 128 |
| Corporate Officer/Principal | 59 |
| Chairman | 59 |
| Independent Dir/Board Member | 35 |
| Chief Tech/Sci/R&D Officer | 25 |
Sterkste connecties
| Insiders | |
|---|---|
| Iain Ross | 41 |
| Simon Cartmell | 39 |
| John Berriman | 24 |
| Bryan Geoffrey Morton | 22 |
| Michael Owen | 20 |
| Paul Harper | 20 |
| Timothy Corn | 20 |
| Martin Walton | 16 |
| Mark James Docherty | 14 |
| Olav Hellebø | 13 |
| Claudia D'Augusta | 12 |
| Richard Beckman | 12 |
| Barbara Staehelin | 10 |
| Michael Elliot Hunt | 8 |
| Julian Howell | 8 |
- Beurs
- Insiders
- John Hawkins
- Bedrijfsconnecties
